Clinical Trials Logo

Clinical Trial Summary

Citrulline is an amino acid produced in the intestine and in the liver, but the liver does not contribute significantly to circulating citrulline concentrations. The intestine is thus the only organ that normally releases significant amounts of citrulline into the blood stream. The investigators have designed a study looking at the value of measuring plasma citrulline concentration in patients with tropical enteropathy of mixed HIV status. The focus will be on the ability of the intestine to sustain the individual concerned from a nutritional standpoint. The investigators hypothesise that plasma citrulline concentration is a marker of small bowel absorptive integrity and an appropriate surrogate for HIV related enteropathy.


Clinical Trial Description

Preliminary studies reported that plasma citrulline concentrations may be a reliable biochemical marker for intestinal dysfunction and absorptive enterocyte mass. The relationship between citrulline concentration and intestinal function has been supported in other studies including those examining rejection in small bowel allografts. Concentrations of citrulline are dramatically reduced in cases of mucosal damage (e.g. moderate graft rejection or viral enteritis)and strongly correlate (inversely) with severity on biopsy. Plasma citrulline concentration is lower also in patients with villous atrophy (24±13µmol/L)than in healthy subjects (40±10µmol/L)and patients with anorexia nervosa (39±9µmol/L).Experimental studies have been carried out also in assessing the value of citrulline as a marker for severity of small bowel epithelial damage from radiation and viral infections. The plasma citrulline was shown to be a simple, non invasive and sensitive essay to monitor and quantify radiation and/or chemotherapy induced small bowel damage in mice and humans. Otherwise, the literature on citrulline as a potential marker of intestinal and nutritional integrity is young and consistent data for specific conditions as for HIV enteropathy are missing.We hypothesise that plasma citrulline concentration is a marker of small bowel absorptive integrity and an appropriate surrogate for HIV related enteropathy. ;


Study Design

N/A


Related Conditions & MeSH terms


NCT number NCT00816842
Study type Observational
Source Azienda Ospedaliero-Universitaria di Parma
Contact
Status Completed
Phase N/A
Start date October 1998
Completion date September 2008

See also
  Status Clinical Trial Phase
Completed NCT00872092 - Validation of Breath Tests in Diagnosing Small Bowel Bacterial Overgrowth N/A
Completed NCT00138879 - Citrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn's Disease Patients N/A
Completed NCT03543540 - Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease Phase 1
Recruiting NCT05209568 - Immune Responses to Gluten N/A
Completed NCT01141998 - Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption N/A
Active, not recruiting NCT03644069 - A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD) Phase 2
Completed NCT00662675 - A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency Phase 3
Suspended NCT03462979 - Effects of Home Gluten Immunogenic Peptide Testing on Children With Celiac Disease N/A
Not yet recruiting NCT00163813 - The Early Nasojejunal Tube to Meet Energy Requirements in Intensive Care (ENTERIC) Study N/A